论文部分内容阅读
目的研究黄芪皂苷组分干预脾虚水湿不化证大鼠血浆内源性代谢物的变化,探求黄芪皂苷组分对脾虚水湿不化证的干预作用。方法采用高效液相-飞行时间质谱仪检测大鼠血浆内源性代谢物信息,利用主成分分析和偏最小二乘判别分析研究对照组、模型组以及黄芪皂苷组之间的代谢差异,确定潜在生物标志物。结果对照组、模型组以及黄芪皂苷组代谢模式明显不同,共鉴定11个生物标志物,其通路主要涉及甘油磷脂代谢、鞘脂代谢、淀粉与蔗糖代谢和花生四烯酸代谢等。结论黄芪皂苷组分可能通过干预溶血磷脂酰胆碱导致的脂肪代谢紊乱、脂肪酸进入线粒体减少导致的能量供给不足、肠道功能失调等一系列代谢紊乱对脾虚水湿不化证起到治疗作用。
Objective To study the effect of astragaloside on plasma endogenous metabolites in rats with spleen-asthenia-dampness syndrome and to explore the intervention effect of astragaloside on the syndrome of spleen-asthenia-dampness syndrome. Methods The plasma endogenous metabolites of rats were detected by HPLC-TOF MS. The difference of metabolism between control group, model group and astragaloside group was studied by principal component analysis and partial least squares discriminant analysis to determine the potential Biomarkers. Results The metabolic patterns of the control group, the model group and the astragaloside group were significantly different. A total of 11 biomarkers were identified. The pathways mainly involved glycerophospholipid metabolism, sphingolipid metabolism, starch and sucrose metabolism and arachidonic acid metabolism. Conclusions Astragaloside may play a therapeutic role in a series of metabolic disorders such as spleen deficiency and water dampness syndrome by interfering with dyslipidemia induced by lysophosphatidylcholine, insufficient energy supply caused by fatty acid entering into mitochondria and intestinal dysfunction.